Coya Therapeutics (COYA) announces completion of patient enrollment of an investigator-initiated, proof-of-concept, open-label study with low-dose IL-2 and CTLA4-Ig combination treatment in patients with Frontotemporal Dementia. The study is led by Dr. Alireza Faridar and Dr. Stanley Appel at the Houston Methodist Neurological Institute with funding from The Peggy and Gary Edwards Endowment Fund. Study patients received subcutaneously administered CTLA4-Ig, followed by a 5-day course of low-dose IL-2 every four weeks, for a total of 22 weeks of dosing and follow-up. Study completion is anticipated in Q4 2025 with topline to follow.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COYA:
- Promising Outlook for COYA 302 Amidst Phase 2 Trial and Near-Term Catalysts Justifies Buy Rating
- Coya Therapeutics launches ALSTARS Trial to study efficacy of COYA 302
- Coya Therapeutics’ COYA 303 shows anti-inflammatory effect in animal study
- Coya Therapeutics’ COYA 302 ALS trial accepted by NEALS research consortium
- Coya Therapeutics Receives $4.2M Milestone Payment